Drug Discovery World

NOVEMBER 28, 2023

An experimental drug has shown potential as a disease-modifying therapy for Parkinson’s disease, according to a new study published in Nature Communications. Parkinson’s disease is highly associated with mitochondrial dysfunction. Mission is planning to initiate a MTX325 Phase I trial in humans in early 2024.

Disease 130

Disease Therapies Medical Schools Trials 130

Drug Discovery World

MAY 17, 2024

This could open new opportunities for a precision medicine approach to heart disease. The target is now being evaluated as part of PlaqueTec’s ongoing BIOPATTERN trial and, if validated, further development will be pursued. This data formed the basis for the current CIA-funded project.

Disease 130

Disease Small Molecule Trials Research 130

Drug Discovery World

SEPTEMBER 21, 2023

A research team from VIB-KU Leuven and the UK Dementia Research Institute has discovered how neurons die in Alzheimer’s disease, opening new pathways for potential future treatments. Alzheimer’s disease (AD) has been classified as public health priority by the World Health Organisation (WHO).

Disease 263

Disease RNA Research Science 263

Drug Discovery World

JUNE 27, 2024

A new Case Study is now available to download for free entitled ‘ Improving physiological relevance in neurological disease drug development. Download ‘ Improving physiological relevance in neurological disease drug development.

Drug Development 130

Drug Development Disease Drugs Science 130

Drug Discovery World

JUNE 10, 2024

VALANX Biotech has reported successful in vivo results in its lead programme VLX101 for the treatment of a range of autoimmune diseases. Protein drugs hold great promise as therapeutics for a wide range of diseases, however, one of the greatest challenges is their short circulation half-life.

Disease 130

Disease Protein Expression Clinical Development Treatment 130

Drug Discovery World

NOVEMBER 23, 2022

Scientists have found a new drug treatment that can slow the progression of neurodegenerative disease in mice. The breakthrough research may offer fresh hope in tackling currently untreatable conditions such as Alzheimer’s disease (AD). .

Disease 243

Disease Drugs Treatment Science 243

Drug Discovery World

SEPTEMBER 12, 2023

Twist Bioscience and Ono Pharmaceutical will combine their efforts to discover and develop novel antibodies for the treatment of autoimmune diseases. This collaboration… has the potential to lead to future breakthrough treatment options for patients with autoimmune diseases.”

Disease 182

Disease Pharmaceuticals Production Treatment 182

Drug Discovery World

FEBRUARY 28, 2024

Induced pluripotent stem cell (iPSC)-derived cells are a significant resource for disease modelling. They allow the use of cells directly from affected patients and have the potential to guide these cells towards multiple lineages.

Disease 130

Disease Drugs 130

Drug Discovery World

APRIL 30, 2024

Four new LifeArc Translational Centres for Rare Diseases have been created to give people living with rare medical conditions access to improved tests and treatments. They aim to tackle barriers that ordinarily prevent new tests and treatments reaching patients with rare diseases and speed up the delivery of rare disease treatment trials.

Research 130

Research Disease Trials Treatment 130

Drugs.com

JULY 23, 2024

TUESDAY, July 23, 2024 -- A single drop of blood might be able to predict the onset of dozens of diseases, a new study claims.Analysis of the protein “signatures” in a droplet of blood can predict 67 diseases, including blood cancers, degenerative n.

Disease 111

Disease 111

Science Daily: Pharmacology News

APRIL 11, 2024

New hypothesis paper builds on a growing scientific consensus that Parkinson's disease route to the brain starts in either the nose or the gut and proposes that environmental toxicants are the likely source.

Disease 144

Disease 144

Drug Discovery World

JANUARY 11, 2024

Researchers have used messenger RNA (mRNA) to create an effective therapy for a rare liver disease in preclinical studies, demonstrating the technology’s potential therapeutic use in people. Patients affected by the disease are found to also experience an imbalance of glutathione regulation, which is important for liver detoxification.

Disease 147

Disease Research RNA Therapies 147

Drug Discovery World

NOVEMBER 22, 2022

Currently, no effective cure or treatment for Huntington’s disease exists. Download this new App Note from bit.bio to learn: How Charles River Laboratories characterised the phenotype of a human iPSC-derived Huntington’s disease model from bit.bio over 38 days in vitro with high-density microelectrode arrays from MaxWell Biosystems.

Disease 130

Disease Research Laboratories Treatment 130

Drug Discovery World

APRIL 8, 2024

Their research signals a transformative leap in liver disease management, addressing both inflammation and fibrosis. Metabolic dysfunction-associated steatotic liver disease (MASLD) is a burgeoning global health concern, posing a significant threat to public health and escalating the burden on healthcare resources.

Disease 130

Disease Treatment Pharmacokinetics Clinical Trials 130

Drug Discovery World

MAY 15, 2024

Dr Catherine Beech , CEO at Exonate and Dr Pete Adamson , CSO at Breye Therapeutics discuss the need for better therapies to treat diabetic retinal disease and current progress in the field. Specific numerical values (steps) denote the severity of NPDR, with 47-53 describing the moderately severe disease. orally administered compounds.

Disease 162

Disease Treatment Therapies Pharmaceuticals 162

Drug Discovery World

FEBRUARY 29, 2024

For Rare Disease Day 2024, Diana Spencer provides a round-up of the latest breakthroughs in the treatment of rare disease. million from the French government to advance the development of a gene therapy for the treatment of cerebrotendinous xanthomatosis (CTX), a rare neurodegenerative disease.

Disease 130

Disease Treatment RNA Clinical Trials 130

Drug Discovery World

MAY 14, 2024

In 2023, the SELECT trial reported that adults with overweight or obesity but not diabetes taking semaglutide for more than three years had a 20% lower risk of heart attack , stroke, or death due to cardiovascular disease, and lost an average 9.4% of their bodyweight.

Disease 147

Disease Clinical Trials Drugs Trials 147

Drug Discovery World

MARCH 21, 2024

Focusing on rare conditions could significantly reduce the burden of kidney disease, according to a new study led by University College London (UCL) and the UK Kidney Association. The study, published in The Lancet to mark World Kidney Day on 14 March, draws on the largest rare kidney disease dataset ever created.

Disease 130

Disease Treatment Hospitals Therapies 130

Drug Discovery World

JANUARY 31, 2024

In aggregate, the 72-week data with atacicept are consistent with a profile of true disease modification in IgAN. These cytokines are members of the tumour necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases, including IgAN and lupus nephritis. PLOS ONE 2015). “We

Disease 130

Disease Clinical Trials Drugs Trials 130

Drug Discovery World

JUNE 27, 2024

The post Improving physiological relevance in neurological disease drug development appeared first on Drug Discovery World (DDW).

Drug Development 130

Drug Development Disease Drugs Science 130

Drug Discovery World

MARCH 6, 2024

This second ODD allows research and development of a therapy for another form of the disease, Isolated Hypomyelination. Dan Williams, CEO at SynaptixBio, said; “This ODD is a huge boost to our efforts in tackling these devastating, life-limiting rare diseases.

FDA 130

FDA Disease Therapies Drugs 130

Drug Discovery World

MARCH 15, 2024

Biotechnology company Allyx Therapeutics has reported positive Phase Ib clinical data for its lead compound, ALX-001, a first-in-class, synapse-targeted, disease-modifying oral therapy in development for neurodegenerative diseases. The findings were presented at the AD/PD 2024 Conference in Lisbon.

Disease 130

Disease Trials Small Molecule Pharmacokinetics 130

Drug Discovery World

AUGUST 23, 2022

A Phase I/II clinical trial targeting a treatment for Huntington’s Disease (HD) using a gene therapy has been given the clearance to go ahead in France. . There are currently no approved disease modifying therapies for Huntington’s Disease. In 2019, BV-101 was granted orphan drug designation in the European Union. .

Therapies 246

Therapies Disease Trials Clinical Trials 246

Drug Discovery World

FEBRUARY 8, 2024

COUR Pharmaceuticals is a clinical-stage biotechnology company developing therapies to treat patients with autoimmune and inflammatory diseases. COUR’s therapies are based on its antigen-specific immune tolerance platform and are designed to reprogramme the immune system to address the underlying root cause of immune-mediated diseases.

Disease 130

Disease Therapies Pharmaceuticals Clinical Trials 130

Drug Discovery World

SEPTEMBER 29, 2023

AI-driven drug discovery company Insilico Medicine and the University of Cambridge have discovered an approach to identify therapeutic targets for human diseases associated with protein phase separation (PPS). “Even more difficult has been to clarify the exact nature of its association with human disease.

Disease 173

Disease Bioinformatics Engineering Research 173

Drug Discovery World

FEBRUARY 27, 2024

Arvinas has commenced dosing in the Phase I clinical trial of ARV-102, its first oral PROTAC (PROteolysis-TArgeting Chimera) protein degrader in development to treat neurodegenerative diseases. The post First PROTAC degrader for neurodegenerative disease enters trials appeared first on Drug Discovery World (DDW).

Trials 130

Trials Disease Clinical Trials Pharmacokinetics 130

Science Daily: Pharmacology News

JUNE 20, 2024

The 3D-printed monitor could someday provide a simple and non-invasive way to track health conditions and diagnose common diseases, such as diabetes, gout, kidney disease or heart disease. A wearable health monitor can reliably measure levels of important biochemicals in sweat during physical exercise.

Disease 117

Disease 117

Drug Discovery World

MARCH 7, 2024

Research published in Cell Genomics has shown that prostate cancer includes two different subtypes of the disease, also known as evotypes. This study is really important because until now, we thought that prostate cancer was just one type of disease.

Disease 147

Disease Medical Schools DNA International 147

Drug Discovery World

SEPTEMBER 5, 2023

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Elfabrio (pegunigalsidase alfa) as an option for treating Fabry disease (or alpha-galactosidase deficiency). Fabry disease is a rare genetic disease affecting approximately 1,150 people in England.

Disease 130

Disease Therapies Treatment Drugs 130

Drug Discovery World

APRIL 8, 2024

Class B GPCRs are recognised as important targets for new medicines, particularly in chronic endocrine and metabolic diseases. grant supports drug discovery in metabolic diseases appeared first on Drug Discovery World (DDW). Diana Spencer, Senior Digital Content Editor, DDW The post €1.6m

Disease 130

Disease Small Molecule Drugs Treatment 130

Drug Discovery World

MARCH 6, 2024

“Their guidance will be invaluable as we soon advance our lead candidate, RNDP-001, into the clinic for the treatment of Parkinson’s disease.” The potentially curative nature of RNDP-001 for Parkinson’s disease could dramatically alter outcomes for patients with very few treatment options.”

Therapies 130

Therapies Disease Clinical Trials Treatment 130

Drug Discovery World

DECEMBER 6, 2022

CAR-T therapy can be used to eliminate unwanted cells that cause autoimmunity, according to the results of a new study in mice with an autoimmune disease similar to multiple sclerosis (MS). . I believe that this is a fully treatable disease, and CAR-T cells may be the way toward much better therapeutics.” .

Disease 214

Disease Therapies Virus Treatment 214

Drug Discovery World

NOVEMBER 8, 2023

Over 19 million 1 hearts succumb to cardiovascular disease yearly, while around 10 million 2 lives are claimed by cancer every year. By prioritising treatments for diseases with high mortality rates a standardised approval process can be established. This was the challenge embraced by researchers at John Hopkins University.

Clinical Trials 182

Clinical Trials Trials Disease Medical Schools 182

Drug Discovery World

NOVEMBER 14, 2023

DDW’s Megan Thomas looks at how different diseases will benefit from the success of therapeutic antibodies. The work is continuous for this disease target. On 6 January 2023, the FDA approved lecanemab-irmb via the Accelerated Approval pathway for the treatment of Alzheimer’s disease.

Disease 147

Disease FDA Approval Treatment FDA 147

Drug Discovery World

FEBRUARY 5, 2024

One-third (32%) of rare disease patients are not aware they can access unlicensed medicines through Early Access Programmes, new research has revealed. The new data was released by pharma company Clinigen to mark the start of Rare Disease Month.

Disease 130

Disease Pharma Companies Licensing Licensing 130

Drug Discovery World

FEBRUARY 13, 2024

Systemic sclerosis is a chronic, progressive, autoimmune disease characterised by inflammation and fibrosis, such as uncontrolled scar tissue formation, in skin and various internal organs. Around 100,000 people in the EU are affected by SSc and up to 80% of these may develop interstitial lung disease (ILD).

Disease 130

Disease Treatment Small Molecule Pharmacokinetics 130

Drug Discovery World

OCTOBER 31, 2023

Professor Andy Whiting and Dr Tony Lockett discuss how specific levels of a protein could be used to advance drug development in neurodegenerative diseases. These parameters aim to measure the progression of disease over time by looking at the functional or observable change in a patient.

Drug Development 147

Drug Development Disease Drugs Clinical Trials 147